Riskpilot← Back to searchSign inGet full accessFinurlig AB
ABActiveOrg 5590600358Rackeby Degeberg 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20160 employees
Revenue 2025
SEK 0
EBITDA margin
—
+31% vs 2024
Equity ratio
79.9%
Financial strength
Net profit 2025
SEK -18K
+24% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -19K | +31% |
| Net profit | SEK -18K | +24% |
| Total assets | SEK 120K | -26% |
| Equity | SEK 96K | +117% |
| Employees | 0 | — |
Legal name
Finurlig AB
Org number
5590600358
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22 april 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva e-handel, grossistverksamhet och produkt- utveckling av hjälpmedel-, läromedel-, leksaker-, kläder-, sjuk- vårdsartiklar och vardagsartiklar för barn och unga med funk- tionsnedsättningar. Bolaget ska äga och förvalta fast och lös egendom samt aktier-, värdepapper samt med annan angivna verksamheter förenlig verksamhet.
Address
Rackeby Degeberg 2
Phone
+4651012900
Email
annalr.cardell@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 0 | 0 | 0 |
| Staff expenses | — | −134 | −0 | −0 | — |
| EBITDA | 132 | −181 | −65 | −27 | −19 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 132 | −181 | −65 | −27 | −19 |
| Net financials | −16 | 150 | −3 | 3 | 0 |
| Profit before tax | 117 | −30 | −68 | −24 | −18 |
| Tax | −0 | — | — | — | — |
| Net profit | 117 | −30 | −68 | −24 | −18 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 425 | 277 | 127 | 162 | 120 |
| Equity | 167 | 137 | 68 | 44 | 96 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 258 | 140 | 59 | 118 | 24 |
| Total debt | 258 | 140 | 59 | 118 | 24 |
EBITDA margin
-1871700.0%
This company
15.8%
Market median
-11846303% vs market
20212025
Equity ratio
79.9%
This company
38.2%
Market median
+109% vs market
20212025
Return on equity
-19.3%
This company
18.4%
Market median
-205% vs market
20212025
Net profit margin
-1848700.0%
This company
8.1%
Market median
-22823557% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AL Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Finurlig AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Lisbet Rebecka Cardell | Chief Executive Officer | 0 companies |
| Eva Lisbet Marlene Söderholm | Deputy Board Member | 0 companies |
| Carl Gunnar Stefan Cardell | Chairman | 0 companies |